Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-overexpressing solid tumor malignancies


ABSTRACT: 16 patients with HER2+ tumors were enrolled (12 breast, 3 gastric, 1 esophageal). 27 samples (12 primary + 15 metastatic) from the 16 unique patients were assayed on Agilent 60K expression microarrays, and association between expression and response data were evaluated to identify potential biomarker of MK2206 response We conducted a phase 1b study of MK-2206 in combination with weekly paclitaxel 80 mg/m2 and trastuzumab 2 mg/kg in patients with HER2+ malignancies. Dose escalation was performed using a modified toxicity probability interval method. Molecular profiling of archived tissue samples and limited PK analyses were performed.

ORGANISM(S): Homo sapiens

SUBMITTER: Christina Yau 

PROVIDER: E-GEOD-75087 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2016-07-31 | GSE75087 | GEO
2020-05-25 | GSE150509 | GEO
2020-05-25 | GSE150458 | GEO
2016-06-14 | E-GEOD-80591 | biostudies-arrayexpress
2016-06-14 | E-GEOD-80593 | biostudies-arrayexpress
2016-06-14 | E-GEOD-80592 | biostudies-arrayexpress
2020-09-20 | GSE149322 | GEO
2020-09-20 | GSE150575 | GEO
2016-07-06 | E-GEOD-70018 | biostudies-arrayexpress
2015-11-11 | E-GEOD-66999 | biostudies-arrayexpress